August 08, 2008

Faegre & Benson Represents Affinity BioReagents in Acquisition by Thermo Fisher Scientific

Faegre & Benson LLP recently represented Affinity BioReagents, Inc., a Golden, Colorado-based company, in its acquisition by Thermo Fisher Scientific Inc.

With an offering of more than 35,000 reagents, Affinity BioReagents is a leading provider of antibodies, peptides and proteins for life science research. Thermo Fisher Scientific (NYSE: TMO) is a leader in the international health and science community, with over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies.

John R. Marcil, a corporate partner in the firm's Boulder office, served as lead attorney on the deal with support from Matt Stamski.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.